Syndax reports Q3 2026 results, 90% Revuforj revenue growth, CFO transition
Syndax posted $83.3 million in total third-quarter revenue and outlined a slate of fourth-quarter revumenib data readouts as Keith Goldan prepares to hand the CFO role to Aaron Ondrey.
Syndax Pharmaceuticals reported third-quarter 2026 results on November 2, 2026. Revuforj (revumenib) net revenue reached $60.7 million in the third quarter of 2026, a 90% increase over the third quarter of 2025 and an 11% increase over the second quarter of 2026.1 New patients and total prescriptions grew about 20% and 13%, respectively, versus the second quarter of 2026.1 Niktimvo (axatilimab-csfr) net revenue was $67.4 million, up 47% year over year and 12% sequentially.1 Syndax and Incyte co-commercialize Niktimvo, with Syndax recording 50% of net commercial profit; its share came to $22.6 million in collaboration revenue for the quarter.1
The company pointed to several near-term catalysts. Syndax said it expects a major presence at medical meetings in the fourth quarter of 2026, with new data including frontline results from the BEAT AML and SAVE trials, a Phase 1 intensive chemotherapy combination trial, post-transplant maintenance data, real-world evidence, and data from the INTERCEPT trial.1 The RAVEN Phase 2 trial of revumenib with venetoclax and azacitidine in newly diagnosed KMT2Ar patients eligible for intensive chemotherapy is expected to begin in the fourth quarter of 2026.1 The MenTain Phase 2 trial, described as the first randomized, placebo-controlled study of revumenib as post-transplant maintenance, is expected to start in the first quarter of 2027.1
On the Niktimvo side, the MAXPIRe Phase 2 trial in idiopathic pulmonary fibrosis did not meet its primary endpoint in October 2026, though safety was consistent with prior studies, and Syndax does not plan further development of axatilimab in IPF.1 Topline data from a Phase 2 trial combining axatilimab with ruxolitinib are expected at a medical meeting in the first quarter of 2027, with Phase 3 corticosteroid-combination data expected in early 2028.1
The company also announced Keith Goldan's retirement as Chief Financial Officer and the appointment of Aaron A. Ondrey to succeed him, effective November 9, 2026.1
On finances, Syndax reported cash, cash equivalents and short- and long-term investments of $551.1 million as of September 30, 2026, with 90.0 million common shares outstanding.1 For full-year 2026, the company continues to expect combined R&D and SG&A expenses of about $400 million excluding stock compensation, and said its cash position along with anticipated product and collaboration revenue and interest income will enable it to reach profitability.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.